The present invention relates to the field of medicinal chemistry and novel 1,3-in 1,4-disubstituted derivatives of piperidine as pharmaceuticall active compounds. These compounds can be in the form of a mixture of enantiomers or in the form of pure enantiomers, in the form of pharmaceutically acceptable salts, as hydrates or solvates thereof. Novel 1,3- and 1,4-disubstituted derivatives of piperidine are inhibitors of the enzyme butyrylcholinesterase. The compounds of the present invention are useful for the treatment of various diseases which may be therapeutically modified by altering the activity of butyrylcholinesterase such as Alzheimer's disease and other dementias
F.32 International patent
COBISS.SI-ID: 4224113The present invention belongs to the field of pharmaceutical industry and relates to novel inhibitors of monoamine oxidase B (MAO-B) for the treatment of acute and chronic diseases such as Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, amyotrophic lateral sclerosis, to the preparation of these compounds and pharmaceutical products that contain these compounds. The characteristic of these compounds is that they bind into the active site through specific noncovalent (polar and hydrophobic interactions) and/or covalent interactions.
F.32 International patent
COBISS.SI-ID: 4497009The project leader Stanislav Gobec is a member of Editorial Board of international journal Acta Chimica Slovenica. The journal publishes papers fom all fields of chemistry, is cited in all major databases and has Impact Factor.
C.06 Editorial board membership
COBISS.SI-ID: 14086149Project leader Stanislav Gobec received Pregl's award in 2017 for outstanding scientific achievements in medicinal chemistry.
E.01 National awards
Project leader S. Gobec had an invited plenary lecture at the congress with international participation, where he presented the results of the work on the project.
B.04 Guest lecture
COBISS.SI-ID: 4810097